Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains.

Literature DB >> 2847640

In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains.

H Maeda¹, A Fujii, K Nakata, S Arakawa, S Kamidono.

Abstract

The in vitro activities of three newly developed quinolone drugs (T-3262, NY-198, and fleroxacin [AM-833; RO 23-6240]) against 10 strains of clinically isolated Chlamydia trachomatis were assessed and compared with those of other quinolones and minocycline. T-3262 (MIC for 90% of isolates tested, 0.1 microgram/ml) was the most active of the quinolones. The NY-198 and fleroxacin MICs for 90% of isolates were 3.13 and 62.5 micrograms/ml, respectively.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1988 PMID： 2847640 PMCID： PMC172348 DOI： 10.1128/AAC.32.7.1080

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

18 in total

1. In vitro activity of the two new 4-quinolones A56619 and A56620 against Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum and Gardnerella vaginalis.

Authors: K H Tjiam; J H Wagenvoort; B van Klingeren; P Piot; E Stolz; M F Michel
Journal: Eur J Clin Microbiol Date: 1986-10 Impact factor: 3.267

2. The action of quinolone carboxylic acids on Chlamydia trachomatis in vitro.

Authors: S J Richmond; C Heppleston; J Bailey
Journal: Biochem Soc Trans Date: 1986-04 Impact factor: 5.407

3. Comparative in vitro activity of RU 28965 against Chlamydia trachomatis.

Authors: R Cevenini; V Sambri; M La Placa
Journal: Eur J Clin Microbiol Date: 1986-10 Impact factor: 3.267

Review 4. Sexually transmitted organisms and infertility: the proof of the pudding.

Authors: W Cates
Journal: Sex Transm Dis Date: 1984 Apr-Jun Impact factor: 2.830

5. Comparison of the in vitro activities of ofloxacin and tetracycline against Chlamydia trachomatis as assessed by indirect immunofluorescence.

Authors: J M Bailey; C Heppleston; S J Richmond
Journal: Antimicrob Agents Chemother Date: 1984-07 Impact factor: 5.191

6. Treatment of nongonococcal urethritis with ciprofloxacin.

Authors: I W Fong; W Linton; M Simbul; R Thorup; B McLaughlin; V Rahm; P A Quinn
Journal: Am J Med Date: 1987-04-27 Impact factor: 4.965

7. In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.

Authors: F W Heessen; H L Muytjens
Journal: Antimicrob Agents Chemother Date: 1984-01 Impact factor: 5.191

Review 6. Quinolones in urology.

Authors: K T Nielsen; P O Madsen
Journal: Urol Res Date: 1989

In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains.

1. In vitro activity of the two new 4-quinolones A56619 and A56620 against Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum and Gardnerella vaginalis.

2. The action of quinolone carboxylic acids on Chlamydia trachomatis in vitro.

3. Comparative in vitro activity of RU 28965 against Chlamydia trachomatis.

Review 4. Sexually transmitted organisms and infertility: the proof of the pudding.

5. Comparison of the in vitro activities of ofloxacin and tetracycline against Chlamydia trachomatis as assessed by indirect immunofluorescence.

6. Treatment of nongonococcal urethritis with ciprofloxacin.

7. In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.

8. Epidemiology of chlamydial infection of the human genital tract: evidence for the existence of latent infections.

9. Activities of new quinoline derivatives against genital pathogens.

10. Isolation of Chlamydia trachomatis from the prostatic cells in patients affected by nonacute abacterial prostatitis.

Review 1. Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

2. In vitro activities of temafloxacin (A-62254) and four other antibiotics against Chlamydia trachomatis.

3. In vitro activity of tosufloxacin (A-61827; T-3262) against selected genital pathogens.

Review 4. Fleroxacin clinical pharmacokinetics.

5. Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections.

Review 6. Quinolones in urology.

Review 7. Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Review 8. Fluoroquinolone antimicrobial agents.

9. In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis.